Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry.: Lymphoma complicating anti-TNF therapy by Mariette, Xavier et al.
Lymphoma in patients treated with anti-TNF: results of
the 3-year prospective French RATIO registry.
Xavier Mariette, Florence Tubach, Haleh Bagheri, Michel Bardet, Jean-Marie
Berthelot, Philippe Gaudin, Denis Heresbach, Antoine Martin, Thierry
Schaeverbeke, Dominique Salmon, et al.
To cite this version:
Xavier Mariette, Florence Tubach, Haleh Bagheri, Michel Bardet, Jean-Marie Berthelot, et al..
Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO
registry.: Lymphoma complicating anti-TNF therapy. Annals of the Rheumatic Diseases, BMJ
Publishing Group, 2010, 69 (2), pp.400-8. <10.1136/ard.2009.117762>. <inserm-00431509>
HAL Id: inserm-00431509
http://www.hal.inserm.fr/inserm-00431509
Submitted on 12 Nov 2009
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

Lymphoma in patients treated with anti-TNF. Results of the 3-year prospective 
French RATIO registry.  
 
 
Mariette X,1* Tubach F,2* Bagheri H,3 Bardet M,4 Berthelot JM,5 Gaudin P,6 
Heresbach D,7 Martin A,8 Schaeverbeke T,9 Salmon D,10 Lemann M,11 Hermine, O 12 
Raphael M,13 Ravaud P2  for the RATIO group. 
 
1 Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Bicêtre, Service de 
rhumatologie, Université Paris-Sud 11, INSERM U802, Le Kremlin-Bicêtre, France  
2 Université Paris 7 Denis Diderot, UFR de médecine ; INSERM, U738 ; AP-HP, Hôpital 
Bichat, Département d’Epidémiologie, Biostatistique et Recherche Clinique, Paris, 
France.  
3 Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de 
Pharmacoépidémiologie et d’Informations sur le Médicament, Unité de 
Pharmacoépidémiologie, EA 3696, Université de Toulouse, Faculté de Médecine, 
Toulouse, France 
4 Hôpital de la Source, Service de médecine interne et rhumatologie, Orléans, France 
5 Hôtel Dieu, Service de rhumatologie, Nantes, France 
6 Centre Hospitalo-Universitaire, Service de rhumatologie, Grenoble, France  
7 Hôpital Pontchaillou, Service des maladies digestives, Rennes, France  
8 Hôpital de Saint Brieuc, Service de rhumatologie, Saint Brieuc, France  
9 Hôpital Pellegrin, Service de rhumatologie, Université Bordeaux II, Bordeaux, France  
10 AP-HP, Hôpital Cochin, Service de médecine interne, Université Paris V, Paris, France  
11 AP-HP, Hôpital Saint Louis, Service de gastro-entérologie, Université Paris 7, Paris, 
France  
12 AP-HP, Hôpital Necker, Service d’hématologie, CNRS UMR 8143, Université Paris V, 
Paris, France  
13 AP-HP, Hôpital Bicêtre, Laboratoire d’hématologie, Université Paris-Sud 11, Le 
Kremlin-Bicêtre, France  
 
* the two authors contributed equally to the work 
Key words: Anti-TNF, Lymphoma, Safety, Rheumatoid arthritis, 
Spondylarthropathies 
 
Running title: Lymphoma complicating anti-TNF therapy 
Word count of the paper: 2,898 
Word count of the abstract: 229 
Number of Tables: 3 
Number of figures: 3 
Number of supplementary files: 1 
Number of supplementary figures: 1 
 
Correspondence and reprint requests to Pr Xavier MARIETTE, Service de 
Rhumatologie, Hôpital de Bicêtre, 78 rue du Général Leclerc, 94275 Le Kremlin Bicêtre. Tel: 
+33 1 45 21 37 58, Fax: +33 1 45 21 37 57. E-mail: xavier.mariette@bct.ap-hop-paris.fr
 1
Abstract 
 
Objective: To describe cases of lymphoma associated with anti-TNF therapy, 
identify risk factors, estimate the incidence and compare risks for different anti-TNF 
agents. 
 
Methods: We designed a national prospective registry (RATIO) from 2004 to 2006, 
for collecting all cases of lymphoma in French patients receiving anti-TNF therapy, 
whatever the indication. We conducted a case-control analysis including two controls 
treated with anti-TNF per case and an incidence study of lymphoma with the French 
population used as reference. .  
 
Results: We collected 38 cases of lymphoma, 31 non-Hodgkin’s lymphoma (NHL) 
(26 B-cell and 5 T-cell), 5 Hodgkin’s lymphoma (HL) and 2 Hodgkin’s-like lymphoma. 
Epstein-Barr virus (EBV) was detected in 2 of 2 Hodgkin’s-like lymphoma, 3 of 5 HL 
and one NHL. Patients receiving adalimumab or infliximab had a higher risk than 
those treated with etanercept: SIR = 4.1 (2.3–7.1) and 3.6 (2.3–5.6) versus 0.9 (0.4–
1.8). The exposure to adalimumab or infliximab versus etanercept was an 
independent risk factor for lymphoma in the case-control study: odds ratio=4.7 (1.3–
17.7) and 4.1 (1.4–12.5), respectively. The sex and age- adjusted incidence rate of 
lymphoma was 42.1 per 100,000 patient-years. The standardized incidence ratio 
(SIR) was 2.4 (95% confidence interval [CI] 1.7–3.2). 
 
Conclusion: Some lymphomas associated with immunosuppression may occur in 
patients receiving anti TNF therapy, and the risk of lymphoma is higher with 
monoclonal-antibody therapy than with soluble-receptor therapy. 
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INTRODUCTION 
 
The risk of lymphoma is increased in several systemic autoimmune diseases, mainly 
Sjögren’s syndrome, systemic lupus erythematosus and rheumatoid arthritis (RA)1. In 
RA, the risk of non-Hodgkin’s lymphoma (NHL) is increased by twofold2 and that of 
Hodgkin’s lymphoma (HL) by threefold.3 Long-lasting inflammatory activity of RA is 
considered the main risk factor of lymphoma by its continuous stimulation of B-cells.4  
The effect of immunosuppressive drugs on the risk of lymphoma remains a 
matter of debate. To date, only the deleterious role of azathioprine has been 
demonstrated for both RA]4 and Crohn’s disease (CD).5 Although withdrawal of 
methotrexate (MTX) treatment can rarely induce regression of Epstein-Barr virus 
(EBV)-associated lymphoproliferation,6 most recent reports did not find any increased 
risk of NHL in RA patients treated with MTX.7 8  
Recent concerns about lymphoma have focused on therapy with anti-TNF 
drugs because of their profound immunoregulatory effect. However, anti-TNF therapy 
could reduce the inflammatory activity of the underlying disease, which is the main 
risk factor for lymphoma in RA.  
In some cohorts of RA patients receiving anti-TNF therapy, the risk of lymphoma was 
not different than that for RA patients not receiving the therapy.7 9-11 However, these 
cohort studies were underpowered to investigate a difference between anti-TNF 
agents in terms of risk of lymphoma.  
We aimed to examine whether patients receiving anti-TNF agents have an 
increased lymphoma risk and to compare risks for different anti-TNF agents,  
described the cases of lymphoma and their outcome, and identified the risk factors of 
lymphoma in patients receiving anti-TNF therapy. 
 
PATIENTS AND METHODS 
 
The French RATIO (Research Axed on Tolerance of bIOtherapies) registry 
was designed by a multidisciplinary group to prospectively collect all cases of 
lymphoma occurring in France from February 1, 2004, to January 31, 2007, in 
patients who were receiving anti-TNF therapy, for whatever the indication. The 
design has been described elsewhere.12 13 The reporting of this study conforms to the 
STROBE statement.14  
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Identification and validation of lymphoma cases 
 
All cases reported to the 31 French pharmaco-vigilance regional centers of 
Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS), or 
pointed out directly to the companies commercializing anti-TNF were collected. In 
addition, physicians from all the different French hospital centers implied either in the 
prescription of TNF blockers (i.e. rheumatology, internal medicine, gastroenterology 
and dermatology departments) and/or in the management of lymphomas (i.e. 
hematology or oncology centers), were directly required to report each newly 
diagnosed case). A direct mail reminder 4 times a year and several communications at 
congresses or in specialized press encouraged them to report cases. 
 
Validation of cases: Included in the RATIO registry were all cases (from all sources) 
with a validated diagnosis of lymphoma according to the International Classification 
of Diseases for Oncology (categories 9590-9599, 9650-9660, 9670-9680, 9690-9699, 
9700-9709, 9710-9719). An expert committee involving 3 experts of lymphoma (XM, 
OH, MR) validated cases by consensus on the basis of the detailed standardized 
case report form and additional documents (hospitalization summary, histological 
results or others). The biopsy specimens of all validated cases were reviewed by the 
same hematopathologist (MR), to validate the diagnosis obtained by histopathology. 
In addition, this hematopathologist assessed all biopsy specimens for presence of 
EBV, detected by Eber in situ hybridization.  
 
 
Risk of lymphoma for patients receiving anti-TNF therapy  
A case-control study was performed..  
Cases: Cases were all validated cases of lymphoma in the RATIO registry with a 
labeling indication for use of anti-TNF treatment (i.e. RA, spondylarthropathy [SpA; 
AS or psoriatic arthritis], UC or CD, or psoriasis). 
Controls: Lymphoma-free patients receiving anti-TNF treatment in a labeling 
indication were included from centers participating in the RATIO registry (thus from 
the same population source) in a global pool of controls. From that pool, we randomly 
selected patients for a database of controls reflecting the proportion of patients 
 4
receiving each of the three anti-TNF drug in France. Two controls per case were 
randomly matched by sex, age (within 5 years) and underlying inflammatory disease 
from this database of controls. We also used a second sample of controls randomly 
selected from the same database of controls, with the same matching criteria 
(second matching).  
 
Incidence study 
Incidence of lymphoma 
We estimated the annual incidence rate of lymphoma in patients treated with anti-
TNF therapy, adjusted for age and sex, with the French population as a reference 
(see supplementary file for details). 
 
 
Statistical analysis 
The number of cases of lymphoma in France during the study period determined the 
sample size. A descriptive analysis was performed for the whole sample. We 
identified the risk factors of lymphoma by both univariate and multivariate analysis 
(conditional logistic regression model). The SIR was calculated for anti-TNF agents 
use as a whole and for agents used individually. We performed subgroup and 
sensitivity analyses. (see supplementary file for details). 
 
Compliance with research ethics standards 
This study was authorized by the ethic committee of AP-HP, GHU Nord (Institutional 
Review Board of Paris North Hospitals, Paris 7 University, AP-HP; authorization 
number 162-08). The registry was reported at clinicaltrials.gov (ClinicalTrials.gov 
Identifier: NCT00224562). 
 
 
RESULTS 
 
Description of the cases 
We collected data on 41 cases of lymphomas, and 38 cases were validated. Among 
them, 31 were NHL (26 B-cell and 5 T-cell), 5 HL and 2 Hodgkin’s-like lymphoma. 
The characteristics of the cases are in Table 1. 
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Biopsy specimens were reviewed for 36 cases (29 NHL, 5 HL and 2 
Hodgkin’s-like lymphomas).  EBV was detected in 2 of 2 Hodgkin’s-like lymphoma, 3 
of 5 HL and one B-cell lymphoproliferation. 
The underlying disease was RA in 27 cases, SpA in 7 cases (AS in 4 cases 
and psoriatic arthritis in 3 cases), CD in 3 cases and primary Sjögren’s syndrome in 
one case. Secondary Sjögren’s syndrome was present in 3 of 27 patients with RA 
and lymphoma. All patients were HIV negative. Most patients (31/38) had received 
only one anti-TNF agent. The 3 patients with CD and lymphoma had previously 
received azathioprine.  
 
Outcome  
Three patients with low-grade NHL received no lymphoma-specific treatment, and 
anti-TNF therapy was stopped. They remained with stable disease, without any 
progression or regression of the lymphoma (follow-up 19.8-37.0 months). Among the 
other patients, 29 received chemotherapy, 3 rituximab alone, and 2 radiotherapy, and 
1 died before receiving chemotherapy. At last follow-up (median follow-up 18.2 
months), 16 cases were in remission, in 3 disease was stable without specific 
treatment of the lymphoma, in 3 disease relapsed, 7 were still being treated and 9 
patients died (24%); 4 of 27 with B-cell NHL, 2 of 5 with T-cell NHL and 3 of 7 with HL 
and Hodgkin’s-like lymphoma. 
 
Time occurrence of lymphoma with anti-TNF therapy 
The median time from onset of anti-TNF treatment and the first symptoms of 
lymphoma was 23.6 months. In 5 patients, lymphoma occurred, but anti-TNF therapy 
had been discontinued 6.1 to 44.1 months before. For these 5 patients, the last anti-
TNF agent received was infliximab for 3 and adalimumab for 2. As indicated in Figure 
1, the relation between cumulative frequency of lymphoma and time from onset of 
anti-TNF therapy appeared to be approximately linear for the first or last anti-TNF 
agent received and did not differ by drug received.  
 
Risk factors of lymphoma for patients receiving anti-TNF therapy 
The case-control study involved 37 cases and 74 controls (as described in the 
methods, the patient treated for Sjögren’s syndrome was not included). The 
repartition of the 3 anti-TNF in the control group corresponded to that found in the 
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country during the 2004-2006 period, with 18% receiving adalimumab, 51% 
etanercept and 31% infliximab. The results of univariate analysis are given in Table 
2.  
On the multivariate analysis (Table 3), 2 factors were independently associated with 
occurrence of lymphoma in patients receiving anti-TNF therapy: anti-TNF treatment 
duration less than 2 years (OR=3.30 [1.17–9.30]) and treatment with infliximab or 
adalimumab versus etanercept (OR=4.12 [1.36–12.49] and OR=4.73 [1.27–17.65], 
respectively). In the case-control study restricted to RA cases, only one factor was 
associated with occurrence of lymphoma: treatment with infliximab or adalimumab 
versus etanercept (OR=6.68 [1.90–23.54]). The ORs of adalimumab or infliximab 
versus etanercept were also very similar with the second matching and in subgroup 
and sensitivity analyses (Figure 2). 
 
Incidence and risk of lymphoma for patients receiving anti-TNF therapy 
compared with the general population 
The main analysis relied on a total number of 57,711 patient-years of use of anti-TNF 
therapy during the 2004-2006 period, as the denominator of the incidence rate. The 
annual incidence rate of lymphoma adjusted for age and sex among patients 
receiving anti-TNF therapy, with the French population as a reference, was 42.1 
(95% CI 6.9-77.2 per 100,000 person-years). The SIR was 2.4 (95% CI 1.7–3.2; 
p<0.0001) (Figure 3). For RA and SpA, the SIR was 2.3 (1.6–3.3; p<0.0001) and 1.9 
(0.9–4.0; p=0.09), respectively. 
Like for the case-control study, the incidence of lymphoma for patients 
receiving anti-TNF therapy differed depending on the agent received. The incidence 
rates for patients receiving etanercept, adalimumab, and infliximab were 15.3 (95% 
CI 0.0-45.6) per 100,000 person-years, 65.1 (95% CI 0.0-160.0) per 100,000 person-
years and 69.1 (95% CI 0.0-150.4) per 100,000 person-years, respectively. The SIRs 
were 0.9 (0.4–1.8; p=0.72), 4.1 (2.3–7.1; p<0.0001), and 3.6 (2.3–5.6; p<0.0001), 
respectively. We found a difference between etanercept and monoclonal-antibody 
therapy in the main analysis and in the sensitivity analyses (Figure 3), even when we 
separately used the different estimates from independent sources, which gave very 
consistent adjusted incidence rates and SIRs (supplementary Figure 1).  
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DISCUSSION 
 
This 3-year study is the first national prospective study recording all cases of 
lymphoma in patients receiving anti-TNF agents, whatever the underlying disease. 
This study allowed us to collect enough cases to differentiate between lymphoma risk 
by use of anti-TNF agent. We found higher incidence of lymphoma with use of the 
two monoclonal-antibody agents (adalimumab and infliximab) than with the soluble-
receptor agent (etanercept).  
 
Three cohorts of RA patients have been used to compare treatment with anti-TNF 
agents and with classical disease-modifying anti-rheumatic drugs in terms of risk of 
lymphoma;7 9-11 and did not found an increased risk with anti-TNF agents (relative risk 
of 1.0 [0.6-1.8]7, 1.35 [0.82-2.11]9 and 1.11 [0.51-2.37]10) These studies failed to 
demonstrate a difference between the treatments in risk of lymphoma due to 
insufficient power. Although the design of the RATIO study has some limitations, it is 
probably the only way (or at least the most powerful way) to investigate difference in 
risk with use of anti-TNF agents. 
 
Our study may have some limitations: 
The denominator of the incidence rate was estimated only. However, because 
each firm evaluated the number of patient-years in the period for each anti-TNF 
agent, the difference in risk between agents we observed cannot be explained by 
different methodologies used for the different agents. Furthermore, in the sensitivity 
analyses, the different estimates from independent sources gave very consistent 
adjusted incidence rates and SIRs (supplementary Figure 1).  
Despite the different strategies used to identify all the cases in the whole country, we 
cannot exclude that some cases were missed. We make the assumption that 
reporting was equal with each biologic.. Actually, reporting of adverse events could 
be lower in patients treated sub-cutaneously (SC; i.e. etanercept and adalimumab) 
outside the hospital. But, in France, the SC-treated patients are mandatory seen by 
hospital physicians initially and yearly for renewal. Moreover, the lack of AE reporting 
is a main issue for minor side effects but not for life-threatening side effects, 
particularly lymphomas that are a major concern for physicians and patients 
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regarding anti-TNF agents. Furthermore, the patients treated with anti TNF agents 
that have lymphomas could be notified to RATIO by the anti TNF agent prescribor 
(rheumatologist, gastro-enterologist, internist or others), by the onco-haematologist, 
or by the pharmacovigilance regional center. Finally, we found that the risk of 
lymphoma was similar for adalimumab and infliximab, that share the same 
mechanism of action (different from the one of etanercep), but adalimumab is a S.C. 
anti TNF agent and infliximab I. V. anti TNF agent.  
     
Finally, the cumulative activity of the disease, known as a risk factor of 
lymphoma at least for RA patients,4 could be different among patients receiving the 
different anti-TNF agents. Indeed, disease in patients receiving therapy at the 
beginning of anti-TNF availability (before 2002), was probably more severe, and such 
patients received exclusively infliximab (the only anti-TNF available in France at that 
time). However, patients with anti-TNF onset before 2002 did not have a higher risk 
of lymphoma than others (anti-TNF onset before 2002: OR=1.3 [0.5–3.7]; p=0.60). 
Furthermore, the comparison between the type of drug used and risk was adjusted 
on the time from onset of anti-TNF treatment (Table 3). In addition, indirect markers 
of disease activity (median duration of the inflammatory underlying disease, 
percentage of patients treated with steroids, frequency of positive rheumatoid factor 
and anti-CCP in RA patients) were not greater in patients treated with infliximab or 
adalimumab than in those treated with etanercept (data not shown). Lastly, the 
impact of a putative difference in duration of exposure and in disease activity 
depending on year of introduction of the anti-TNF agent probably cannot explain the 
difference in incidence of lymphoma depending on the type of anti-TNF agent used 
because we observed exactly the same increased risk of lymphoma for patients 
receiving infliximab, which was introduced in 1999, and adalimumab, which has been 
available since 2004, whereas the risk was lower with use of etanercept, available in 
France from early 2003. 
 
The strengths of this study are that our population of focus was the whole French 
population receiving anti-TNF therapy, whatever the indication for use, rather than a 
limited and selected population included in a specific cohort study. Furthermore, all 
the cases were validated by an expert committee, and the biopsy specimens were 
centralized, reviewed by the same hematopathologist and tested for EBV.  
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 Even though the overall risk of lymphoma in RA patients treated with anti-TNF 
therapy does not appear to differ greatly from what is expected in a population of 
patients with inflammatory diseases,1-3  the risk differs depending on the anti-TNF 
drug used (higher risk with monoclonal anti-TNF therapy, adalimumab and 
infliximab). This difference in risk depending on agent was found in the case-control 
study and confirmed in the comparison of incidence with the general population, 
which supports the robustness of this finding. A meta-analysis assessing cancers in 
randomized controlled trials using monoclonal anti-TNF therapy, adalimumab and 
infliximab in RA patients revealed 10 cases of lymphoma (4 in randomized phases of 
trials and 6 in extension phases) in the treated groups (3,493 patient-years) and 0 in 
placebo groups (1,512 patient-years).15 The same analysis of randomized controlled 
trials with etanercept of 2,484 patient-years with etanercept treatment and 1,072 
patient-years with control therapy revealed 2 cases of lymphoma with etanercept 
therapy and none with control therapy.16 Finally, cases of hepatosplenic T-cell 
lymphoma have been described in adolescents and young adults with CD treated 
with monoclonal antibodies and azathioprine combined (10 cases with infliximab17 
and 3 cases with adalimumab.18)  
 
The absence of intrinsic increased risk of lymphoma in SpA patients makes this 
population an ideal model for assessing the anti-TNF-related risk of lymphoma. 19 In 
our study, no significant increase in risk of lymphoma was observed in patients 
receiving anti-TNF therapy for SpA. However, no definitive conclusion may be drawn 
from our data based on very few cases of lymphoma in SpA patients. Some of the 
cases we observed reinforce the likelihood of a causal role of anti-TNF therapy in risk 
of lymphoma. In one patient with AS who never received other immunosuppressors, 
including MTX, EBV-associated Hodgkin’s-like lymphoma developed after treatment 
with infliximab. We observed 3 cases of EBV-induced lymphoproliferation: 2 cases of 
EBV-associated Hodgkin’s-like lymphomas with infliximab treatment (one with RA, 
one with AS described above) and 1 case of EBV-associated B-cell NHL in a patient 
with RA treated with adalimumab. These 3 cases demonstrate that lymphomas 
similar to post-transplant lymphoproliferative disease may occur, even rarely, with 
anti-TNF treatment. In the literature, one case of EBV-associated lymphoproliferation 
in a patient with RA treated with etanercept regressed after withdrawal of the drug. 20 
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Another case of hypopharynx MALT lymphoma not associated with EBV regressed 
spontaneously after withdrawal of infliximab. 21 
 
The pathophysiological mechanism inducing a higher risk of lymphoma in patients 
receiving anti-TNF therapy remains unclear.  A direct action of TNF or anti-TNF on B 
cells was hypothesized, but no increase in survival or apoptosis with TNF or 
infliximab treatment was found. 23  
Actually, in inflammatory diseases and especially RA, the 3 anti-TNF agents 
may have opposite effects: a beneficial effect due to the decrease in activity of the 
disease and a deleterious effect due to immunomodulatory activity, which may 
concern EBV-associated lymphoma but also more classical lymphoma. The 
mechanism of action of this deleterious effect is still unknown but could be related to 
T-cell control of viruses such as EBV or of other mechanisms of lymphomagenesis. 
This T-cell control may require integrity of membrane TNF, which is upregulated in 
activated T cells. Some studies suggest a higher efficacy of anti-TNF monoclonal-
antibody treatment than TNF soluble receptor therapy for inhibiting  membrane TNF 
signaling,22 which  could lead to a decreased immune surveillance of different 
mechanisms of lymphomagenesis.  
 
In conclusion, some lymphomas associated with immunosuppression may occur in 
such patients. The incidence of lymphoma is higher with monoclonal-antibody agents 
than with the soluble receptor. This may be due to a difference of targeting 
membrane TNF, leading also to difference of effectiveness in some diseases such as 
Crohn’s disease or granulomatous diseases. 
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Table 1. Characteristics of the 38 lymphoma cases 
 
  
All lymphoma 
(n=38) 
Lymphoma  
in RA patients 
(n=27) 
Age (years) 61.3 ± 12.3 (63.5) 63.4 ± 11.8 
(64.0) 
Sex (female) 17 (44.7%) 15 (55.6%) 
Underlying inflammatory 
disease 
     RA 
     Ankylosing spondylitis 
     Psoriatic arthritis 
     Crohn’s disease 
     Primary Sjögren’s syndrome 
 
 
27 (71.0%) 
4 (10.5%) 
3 (7.9%) 
3 (7.9%) 
1 (2.6%) 
 
 
 
27 
Duration of the underlying 
inflammatory disease before 
the first symptoms of 
lymphoma (years) 
 
 
11.0 ± 8.6 (8.9) 
 
11.3 ± 9.0 (8.2) 
Activity of the underlying 
inflammatory disease at the 
time of diagnosis of 
lymphoma 
Null 
Fair  
Moderate 
High  
 
 
 
 
 
9 (26.5%) 
8 (23.5%) 
7 (20.6%) 
10 (29.4%) 
 
 
 
 
7 (29.2%) 
5 (20.8%) 
5 (20.8%) 
7 (29.2%) 
Lymphoma histological 
subtype 
 
Non-Hodgkin’s lymphoma 
- B-cell lymphoma 
     Diffuse large B-cell 
     Follicular B-cell 
     Marginal zone B-cell 
     Lymphocytic  
     Others 
 
- T-cell lymphoma 
     Pleiomorphic T-cell 
     Sezary T-cell 
     Lymphoblastic T-cell 
      
Hodgkin’s and Hodgkin’s-like 
lymphoma 
-    Hodgkin-like 
-    Scleronodular  
 
 
 
31 (81.6%) 
26 (83.9%) 
14 
4 
2 
2 
4 
 
5 (16.1%) 
3 
1 
1 
 
7 (18.4%) 
 
2 
2 
 
 
 
22 (81.5%) 
20 (74.1%) 
11 
3 
1 
1 
4  
 
2 (7.4%) 
2 
0 
0 
 
5 (18.5%) 
 
1 
1 
 16
 17
-    mixed cellularity 3 3 
Anti-TNF treatment 
Number of anti-TNF agents 
received 
     1 
     2 
     3 
 
First anti-TNF agent received 
Adalimumab 
Etanercept 
Infliximab 
 
Last anti-TNF agent received 
Adalimumab 
Etanercept 
Infliximab 
 
Ever used Adalimumab  
Ever used Etanercept  
Ever used Infliximab  
Ever used Infliximab or 
adalimumab  
 
Time since first anti-TNF 
treatment began§ (months) 
 
Time since last anti-TNF 
treatment began§ (months) 
 
 
 
31 (81.6%) 
6 (15.8%) 
1 (2.6%) 
 
 
 
8 (21.0%) 
11 (29.0%) 
19 (50.0%) 
 
 
12 (31.6%) 
7 (18.4%) 
19 (50.0%) 
 
12 (31.6%) 
13 (34.2%) 
21 (55.3%) 
32 (84.2%) 
 
 
27.0 ± 16.7 (23.6) 
 
 
23.7 ± 16.0 (22.7) 
 
 
 
20 (74.1%) 
6 (22.2%) 
1 (3.7%) 
 
 
 
8 (29.6%) 
8 (29.6%) 
11 (40.7%) 
 
 
12 (44.4%) 
4  (14.8%) 
11 (40.7%) 
 
12 ( 44.4%) 
10 ( 37.0%) 
13 ( 48.1%) 
24 (88.9%) 
 
 
29.2 ± 17.2 
(25.6) 
 
24.6 ± 16.6 
(22.5) 
DMARD use during the last 5 
years 
Methotrexate 
Azathioprine 
Leflunomide 
 
 
27 (71.1%) 
3 (7.9%) 
7 (18.4%) 
 
 
 
23 (85.2%) 
0 ( 0.0%) 
7 (25.9%) 
 
RA: rheumatoid arthritis; DMARD: disease-modifying anti-rheumatic drug 
Continuous variables are mean ± SD (median) 
Categorized variables are numbners (%) 
§ Time from onset of first/last anti-TNF treatment to first symptoms of lymphoma  
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Table 2: Risk factors of lymphoma for patients receiving anti-TNF agents (univariate analysis: main analysis and analysis restricted to rheumatoid arthritis 
[RA] patients)  
  
 All lymphoma 
(37 cases and 74 controls) 
Lymphoma in RA patients 
(27 cases and 54 controls) 
 Cases 
(n=37) 
Controls 
(n=74) 
OR 
[95% CI] 
p 
value 
Cases 
(n=27) 
Controls 
(n=54) 
OR 
[95% CI] 
p 
value 
Duration of the underlying 
inflammatory disease (years) 
 
 
11.07 (8.75) 
 
16.5 ± 12.4 
 
0.95 [0.91 – 1.00] 
 
0.047 
 
11.26 (8.97) 
 
17.46 (12.12) 
 
0.94 [0.88 – 1.00] 
 
0.06 
Activity of the underlying 
inflammatory disease at the 
time of diagnosis of lymphoma 
Null, fair, or moderate 
High  
 
 
 
 
23 ( 69.7%) 
10 ( 30.3%) 
 
 
 
42 (85.7%) 
7 (14.3%) 
 
 
 
1 
2.04 [0.65 – 6.44] 
 
 
 
 
0.22 
 
 
 
17 ( 70.8%) 
7 ( 29.2%) 
 
 
 
33 ( 89.2%) 
4 ( 10.8%) 
 
 
 
1 
2.84 [0.69 – 11.67] 
 
 
 
0.15 
Number of anti-TNF agents 
received 
     1 
     2 or 3 
 
 
 
30 ( 81.1%) 
7 ( 18.9%) 
 
 
56 ( 75.7%) 
18 ( 24.3%) 
 
 
 
1 
0.71 [0.25 – 1.97] 
 
 
0.51 
 
 
20 ( 74.1%) 
7 ( 25.9%) 
 
 
40 ( 74.1%) 
14 ( 25.9%) 
 
 
1 
1.00 [0.33 – 3.04] 
 
 
1.00 
First anti-TNF agent received 
Etanercept 
Adalimumab  
Infliximab 
 
11 ( 29.7%) 
8 ( 21.6%) 
18 ( 48.6%) 
 
30 ( 40.5%) 
9 ( 12.2%) 
35 ( 47.3%) 
 
1 
2.64 [0.74 – 9.41] 
1.38 [0.55 – 3.45] 
 
 
0.33 
 
 
 
 
 
 
  
 
 
 
First anti-TNF agent received 
Etanercept 
Adalimumab or infliximab 
 
 
11 ( 29.7%) 
26 ( 70.3%) 
 
30 ( 40.5%) 
44 ( 59.5%) 
 
1 
1.61 [0.69 – 3.78] 
 
 
0.27 
 
8 ( 29.6%) 
19 ( 70.4%) 
 
26 ( 48.1%) 
28 ( 51.9%) 
 
1 
2.05 [0.79 – 5.27] 
 
 
0.14 
Last anti-TNF agent received 
Etanercept 
Adalimumab 
Infliximab 
 
 
7 ( 18.9%) 
12 ( 32.4%) 
18 ( 48.6%) 
 
33 ( 44.6%) 
13 ( 17.6%) 
28 ( 37.8%) 
 
1 
4.52 [1.39 – 14.71] 
3.00 [1.10 – 8.15] 
 
 
0.03 
   
 
 
 
Last anti-TNF agent received 
Etanercept 
Adalimumab or infliximab 
 
 
7 ( 18.9%) 
30 ( 81.1%) 
 
33 ( 44.6%) 
41 ( 55.4%) 
 
1 
3.40 [1.31 – 8.80] 
 
 
0.012 
 
4 ( 14.8%) 
23 ( 85.2%) 
 
29 ( 53.7%) 
25 ( 46.3%) 
 
1 
6.68 [1.90 – 23.54] 
 
 
0.003 
Time from onset of first anti-         
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TNF treatment¥  
< 2 years 
≥ 2 years 
 
 
20 ( 54.1%) 
17 ( 45.9%) 
 
24 ( 32.4%) 
50 ( 67.6%) 
 
2.71 [1.09 – 6.73] 
1 (Ref) 
 
0.03 
 
14 ( 51.9%) 
13 ( 48.1%) 
 
38 ( 70.4%) 
16 ( 29.6%) 
 
2.46 [0.83 – 7.26] 
1 (Ref) 
 
 
0.10 
Time from onset of last anti-TNF 
treatment¥  
< 2 years 
≥ 2 years 
 
 
 
23 ( 62.2%) 
14 ( 37.8%) 
 
 
31 ( 41.9%) 
43 ( 58.1%) 
 
 
2.37 [1.00 – 5.60] 
1 (Ref) 
 
 
0.05 
 
 
16 ( 59.3%) 
11 ( 40.7%) 
 
 
23 ( 42.6%) 
31 ( 57.4%) 
 
 
2.05 [0.75 – 5.61] 
1 (Ref) 
 
 
0.16 
Year of onset of first anti-TNF 
agent use before 2002 
No 
Yes 
 
 
 
29 ( 78.4%) 
8 ( 21.6%) 
 
 
61 ( 82.4%) 
13 ( 17.6%) 
 
 
1 
1.32 [0.47 – 3.69] 
 
 
 
0.60 
 
 
21 ( 77.8%) 
6 ( 22.2%) 
 
 
42 ( 77.8%) 
12 ( 22.2%) 
 
 
1 
1.00 [0.32 – 3.17] 
 
 
1.00 
Etanercept use  
     Never 
     Ever 
 
 
24 ( 64.9%) 
13 ( 35.1%) 
 
35 ( 47.3%) 
39 ( 52.7%) 
 
1 
0.45 [0.19 – 1.09] 
 
0.08 
 
17 ( 63.0%) 
10 ( 37.0%) 
 
20 ( 37.0%) 
34 ( 63.0%) 
 
1 
0.35 [0.13 – 0.94] 
 
0.04 
Infliximab or adalimumab use  
     Never 
     Ever 
 
 
6 ( 16.2%) 
31 ( 83.8%) 
 
24 ( 32.4%) 
50 ( 67.6%) 
 
1 
2.36 [0.89 – 6.27] 
 
 
0.08 
 
3 ( 11.1%) 
24 ( 88.9%) 
 
21 ( 38.9%) 
33 ( 61.1%) 
 
1 
4.59 [1.27 – 16.56] 
 
 
0.02 
Methotrexate$ 
     No 
     Yes 
 
 
11 ( 29.7%) 
26 ( 70.3%) 
 
18 ( 24.3%) 
56 ( 75.7%) 
 
1 
0.73 [0.29 – 1.87] 
 
 
0.52 
 
4 ( 14.8%) 
23 ( 85.2%) 
 
11 ( 20.4%) 
43 ( 79.6%) 
 
1 
1.50 [0.41 – 5.54] 
 
0.54 
Azathioprine$ 
     No 
     Yes 
 
 
34 ( 91.9%) 
3 (  8.1%) 
 
66 ( 89.2%) 
8 ( 10.8%) 
 
1 
0.43 [0.04 – 4.61] 
 
0.49 
 
27 (100.0%) 
0 (  0.0%) 
 
51 ( 94.4%) 
3 (  5.6%) 
 
1 
- 
 
 
- 
Leflunomide$ 
     No 
     Yes 
 
 
30 ( 81.1%) 
7 ( 18.9%) 
 
58 ( 78.4%) 
16 ( 21.6%) 
 
1 
0.83 [0.30 – 2.34] 
 
0.73 
 
20 ( 74.1%) 
7 ( 25.9%) 
 
38 ( 70.4%) 
16 ( 29.6%) 
 
1 
0.83 [0.30 – 2.34] 
 
0.73 
  Continuous variables are mean (SD) 
  Categorized variables are numbers (%) 
OR: odds ratio 
¥ Time from onset of last anti-TNF treatment and first symptoms of lymphoma for cases, time from onset of last anti-TNF treatment and last 
news for controls 
    $ Treatment during the last 5 years 
Table 3: Risk factors of lymphoma for patients receiving anti-TNF agents 
(multivariate analysis: main analysis and analysis restricted to rheumatoid arthritis 
[RA] patients)  
 
 
All lymphoma 
(37 cases and 74 controls) 
 
 
OR 
[95% CI] 
p value 
Last anti-TNF agent 
received 
Etanercept 
Adalimumab  
Infliximab 
 
 
 
1 
4.73 [1.27 – 17.65] 
4.12 [1.36 – 12.49] 
 
 
 
0.02 
0.01 
Time from onset of first anti-
TNF treatment¥  
< 2 years 
≥ 2 years 
 
 
 
3.30 [1.17 – 9.30] 
1 (Ref) 
 
 
0.02 
   
  
Lymphoma in RA patients 
(27 cases and 54 controls) 
 
Last anti-TNF agent 
received 
Etanercept 
Adalimumab or infliximab 
 
 
 
1 
6.68 [1.90 – 23.54] 
 
 
0.003 
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Figure 1: Time from onset of first and last anti-TNF treatment and first symptoms of 
lymphoma (months) 
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Figure 2: Estimation of the standardized incidence ratio (SIR) for risk of lymphoma 
according to underlying disease, and the histological subtype of lymphoma 
 
 
 
 
 
 
 
 Risk is lower than in 
the French population 
Risk is higher than in 
the French population 
Risk is lower than in 
the French population 
Risk is higher than in 
the French population 
 
SIR = 3.5 [2.2 – 5.7] p<0.0001 n=17 
SIR = 0.6 [0.2 – 1.9] p=0.37 n=3 
* Only INF: n=17, SIR = 3.9 [2.1 – 6.2] 
  Only ADA: n=8, SIR = 3.3 [1.7 – 6.6] 
SIR = 0.7 [0.2 – 1.7] p=0.39 n=4 
SIR = 2.3 [1.6 – 3.3] p<0.0001 n=27 
 
SIR = 3.9 [2.6 – 5.9] p<0.0001 n=23 
SIR = 2.4 [1.7 – 3.2] p<0.0001 n=38 
SIR = 0.9 [0.4 – 2.0] p=0.82 n=6 
SIR = 3.7 [2.6 – 5.3] p<0.0001 n=31 
SIR = 0.9 [0.4 – 1.8] p=0.72 n=7 
SIR = 3.7 [2.5 – 5.4] p<0.0001 n=25* 
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Risk is lower than in 
the French population 
Risk is higher than in 
the French population 
SIR = 2.2 [0.7 – 6.9] p = 0.16 n=3 
SIR = 1.9 [0.9 – 4.0] p=0.09 n=7 
SIR = 1.7 [0.6 – 4.5] p=0.30 n=4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
SIR = 0.7 [0.3 – 1.7] p=0.40 n=5 
SIR = 2.1 [1.5 – 3.0] p<0.0001 n=31 
SIR = 3.4 [2.3 – 5.0] p<0.0001 n=26 
SIR = 3.2 [2.1 – 4.9] p=<0.0001 n=20 
SIR = 0.7 [0.3 – 1.8] p=0.42 n=4 
 
 
Risk is lower than in 
the French population 
Risk is higher than in 
the French population 
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SIR =  8.4 [3.5 – 20.1] p<0.0001 n=5
SIR = 3.4 [0.9 – 13.6] p=0.08 n=2
SIR = 6.9 [2.9 – 16.5] p<0.0001 n=5
SIR = 2.8 [0.7 – 11.1] p=0.15 n=2
SIR = 4.9 [2.3 – 10.2] p<0.0001 n=7
Risk is lower than in 
the French population 
Risk is higher than in 
the French population  
 
 
 
n is the number of cases involved in the calculation (numerator of the incidence rate) 
the plot size relates to the number of patients treated involved in the calculation 
(denominator of the incidence rate)
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Figure 3 : Sensitivity analysis of the results of the case-control analysis: odds ratios 
(ORs) for the risk of being treated with adalimumab or infliximab rather than with 
etanercept in multivariate analysis.  
 
 
 
 
 
 
OR = 4.1 [1.4 – 12.0] p=0.0108 n=36
OR = 3.7 [1.3 – 10.8] p=0.0167 n=37
OR = 4.3 [1.5 – 12.5] p=0.0076 n=37
OR = 6.3 [1.4 – 29.1] p=0.0174 n=20
OR = 3.2 [1.1 – 9.1] p=0.0333 n=30
OR = 6.7 [1.9 – 23.5] p=0.0031 n=27
OR = 4.2 [1.5 – 11.7] p=0.0053 n=33
OR = 4.7 [1.6 – 14.3] p=0.0059 n=31
Risk is higher 
with etanercept 
Risk is higher with 
adalimumab or infliximab 
 
n is the number of cases involved in the calculation  
the plot size relates to the number of patients treated involved in the calculation 
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Supplementary figure 
 
Figure 1: Sensitivity analysis of the estimation of the standardized incidence ratio 
(SIR) for the risk of lymphoma when using the denominator estimated by each 
pharmaceutical company and by the RSI (French Sickness Insurance Fund for self-
employed workers – providing claims data for etanercept and adalimumab). 
 
 
 
 
 
 
Risk is lower than in 
the French population 
Risk is higher than in 
the French population 
SIR = 2.3 [1.7 – 3.1] p<0.0001 
SIR = 2.3 [1.7 – 3.2] p<0.0001
SIR = 2.5 [1.8 – 3.4] p<0.0001 
 
 
 
 
 Risk is lower than in 
the French population 
Risk is higher than in 
the French population 
SIR = 2.0 [1.4 – 2.9] p<0.0001 
SIR = 2.1 [1.4 – 2.9] p<0.0001 
SIR = 2.2 [1.6 – 3.2] p<0.0001 
 26
 
 
SIR = 5.2 [2.5 – 10.8] p<0.0001 
SIR = 4.7 [2.2 – 9.9] p<0.0001 
SIR = 4.7 [2.3 – 9.9] p<0.0001 
Risk is lower than in 
the French population 
Risk is higher than in 
the French population  
 
 
 
 
 
SIR = 0.9 [0.4 – 1.9] p=0.80 
SIR = 0.9 [0.4 – 1.9] p=0.84 
SIR = 1.0 [0.5 – 2.2] p=0.92 
SIR = 0.9 [0.4 – 1.9] p=0.77 
Risk is lower than in 
the French population 
Risk is higher than in 
the French population 
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n is the number of cases involved in the calculation (numerator of the incidence rate) 
the plot size relates to the number of patients treated involved in the calculation 
(denominator of the incidence rate) 
SIR = 4.1 [2.3 – 7.3] p<0.0001 
SIR = 3.4 [1.9 – 6.0] p<0.0001 
SIR = 3.3 [1.9 – 5.8] p<0.0001 
SIR = 3.7 [2.5 – 6.1] p<0.0001 
SIR = 2.8 [1.8 – 4.4] p<0.0001 
SIR = 2.9 [1.6 – 5.1] p<0.0001 
Risk is lower than in 
the French population 
Risk is higher than in 
the French population 
SIR = 3.4 [2.2 – 5.4] p<0.0001 
Risk is lower than in 
the French population 
Risk is higher than in 
the French population 
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